Sunshine Heart (SSH) versus AxoGen (AXGN) Head to Head Review

Sunshine Heart (NASDAQ: SSH) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares Sunshine Heart and AxoGen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sunshine Heart N/A -302.32% -126.49%
AxoGen -27.50% -114.64% -27.71%

Valuation and Earnings

This table compares Sunshine Heart and AxoGen’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Sunshine Heart N/A N/A N/A ($33.63) -0.02
AxoGen $50.02 million 10.03 -$8.05 million ($0.42) -35.95

Sunshine Heart has higher revenue, but lower earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Sunshine Heart, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Sunshine Heart has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Sunshine Heart and AxoGen, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sunshine Heart 0 0 0 0 N/A
AxoGen 0 0 6 0 3.00

Sunshine Heart currently has a consensus target price of $0.23, suggesting a potential downside of 62.47%. AxoGen has a consensus target price of $15.90, suggesting a potential upside of 5.30%. Given AxoGen’s higher probable upside, analysts plainly believe AxoGen is more favorable than Sunshine Heart.

Institutional and Insider Ownership

64.6% of AxoGen shares are held by institutional investors. 3.0% of Sunshine Heart shares are held by insiders. Comparatively, 9.3% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

AxoGen beats Sunshine Heart on 8 of the 10 factors compared between the two stocks.

Receive News & Ratings for Sunshine Heart Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply